When can I stop dual antiplatelet therapy in patients with drug-eluting stents?

Article Figures & Data

TABLE 1

Risk factors for ischemia, stent thrombosis, and bleeding

Ischemia^a	Stent thrombosis^a	Bleeding^b
Advanced age Acute coronary syndrome at presentation Previous myocardial infarction Extensive coronary artery disease Diabetes mellitus Chronic kidney disease	Acute coronary syndrome at presentation Diabetes mellitus Left ventricular ejection fraction < 40% First-generation drug-eluting stent Stent undersizing Stent underdeployment Small stent diameter Greater stent length Bifurcation stents In-stent restenosis	History of bleeding Diabetes mellitus Female Advanced age Low body weight Chronic kidney disease Anticoagulation Chronic nonsteroidal anti-inflammatory drug or steroid therapy Anemia

↵a These factors favor consideration of a longer duration of dual antiplatelet therapy.
↵b These factors favor consideration of a shorter duration of dual antiplatelet therapy.
Reprinted with permission. Circulation 2016; 134(10):e123–e155. Copyright 2016 American Heart Association, Inc.